“…The recent article published in Signal Transduction and Targeted Therapy sheds light on the significance of N6-methyladenosine (m6A) methyltransferase-like protein METTL14 in mitigating the progression of metabolic dysfunction-associated fatty liver disease (MAFLD). 1 In this study, Wang et al elucidated the downregulation of METTL14 in hepatocytes from both MAFLD patients and high-fat diet (HFD)-induced MAFLD mouse models, underscoring its pivotal role in maintaining hepatic lipid and redox homeostasis in normal livers. Dysregulation of METTL14 emerges as a contributing factor to MAFLD development.…”